Takeda to showcase growing pipeline and diversified portfolio of
oncology products at upcoming scientific congresses
Cambridge, mass. & osaka, japan--(business wire)--takeda pharmaceutical company limited (tse: 4502/nyse:tak) today announced that the company will present data at the 55th annual meeting of the american society of clinical oncology (asco), may 31-june 4 in chicago and the 24th congress of the european hematology association (eha), june 13-16 in amsterdam. “we look forward to presenting data at asco and eha that illustrate the continued progress of our portfolio in both clinical research and real-world settings in solid tumors and blood cancers,” said phil rowlands, ph.d., head, oncology therapeutic area unit, takeda. “these data demonstrate our continued commitment to the discovery, development and delivery of medicines for patients with cancers.” at asco, takeda will present data from both its lung portfolio and hematology portfolio. results from a phase 1/2 first-in-human, open-label, multicenter study of tak-788 will be presented orally. the ongoing study is investigating the antitumor activity and safety of tak-788 in patients with locally advanced or metastatic non-small cell lung cancer (nsclc) whose tumors harbor epidermal growth factor receptor (egfr) exon 20 insertion mutations. takeda also will present three posters that demonstrate our commitment to furthering the understanding of patients with anaplastic lymphoma kinase-positive (alk+) nsclc treated with alunbrig® (brigatinib). the phase 3 phallcon trial – an ongoing efficacy study of iclusig® (ponatinib) in combination with reduced-intensity chemotherapy in patients with newly diagnosed philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all) – will be featured in a poster presentation. additional data from the echelon-1 and echelon-2 trials evaluating adcetris® (brentuximab vedotin) as a frontline treatment option in patients with newly diagnosed stage iii and iv hodgkin lymphoma and in cd30+ peripheral t-cell lymphoma, respectively, will also be shared in partnership with seattle genetics. at eha, additional analyses from the tourmaline-mm3 trial, which is investigating ninlaro™ (ixazomib) as a post-transplant maintenance therapy in adult patients with multiple myeloma, will be presented, including quality of life and outcomes in patients who deepened their responses while on ixazomib maintenance. furthermore, preliminary demographics, baseline characteristics and electronic patient-reported outcomes of patients enrolled in the us mm-6 trial, a study of multiple myeloma patients who transitioned from treatment with velcade® (bortezomib) to treatment with ninlaro, will be presented. real-world findings will also be featured at the meeting, including results from insight-mm, a global, prospective, non-interventional, observational study of presentation, treatment patterns and outcomes in multiple myeloma by age and geographical region. adcetris will be featured in encore presentations including three-year results from the echelon-1 trial, which will be presented during an oral, as well as results from the echelon-2 trial. the eight takeda-sponsored abstracts accepted for presentation during asco 2019 and 11 abstracts at eha 2019 include: asco annual meeting 2019 note: all times listed are in central daylight time tak-788 antitumor activity of tak-788 in nsclc with egfr exon 20 insertions. abstract 9007. oral presentation. monday, june 3, 10:12 – 10:24 a.m. (hall b1). alunbrig (brigatinib) brigatinib (brg) versus crizotinib (crz) in asian versus non-asian patients (pts) in the phase 3 alta-1l trial. abstract 9026. poster presentation. sunday, june 2, 8 – 11 a.m. (hall a). phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (alk)−positive, advanced non–small cell lung cancer (nsclc) that progressed on alectinib or ceritinib. abstract tps9115. poster presentation. sunday, june 2, 8 – 11 a.m. (hall a). health-related quality of life (hrqol) results from alta-1l: phase 3 study of brigatinib vs crizotinib as first-line (1l) alk therapy in advanced alk+ non-small cell lung cancer (nsclc). abstract 9084. poster presentation. sunday, june 2, 8 – 11 a.m. (hall a). iclusig (ponatinib) phase 3 phallcon study: ponatinib (pon) vs imatinib (im) with reduced-intensity chemotherapy (ct) in patients (pts) with newly diagnosed philadelphia chromosome–positive (ph+) all. abstract tps7061. poster presentation. monday, june 3, 8 – 11 a.m. (hall a). adcetris (brentuximab vedotin) brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma: three-year update of the echelon-1 study. abstract 7532. poster presentation. monday, june 3, 8 – 11 a.m. (hall a). response to brentuximab vedotin by cd30 expression: results from five trials in ptcl, ctcl, and b-cell lymphomas. abstract 7543. poster presentation. monday, june 3, 8 – 11 a.m. (hall a). response to a+chp by cd30 expression in the echelon-2 trial. abstract 7538. poster presentation. monday, june 3, 8 – 11 a.m. (hall a). eha 24th congress note: all times listed are in central european time multiple myeloma / ninlaro (ixazomib) deepening responses seen with ixazomib maintenance post-autologous stem cell transplantation (asct) are associated with prolonged progression-free survival – analysis from the tourmaline-mm3 study. abstract ps1382. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). health-related quality of life (hrqol) outcomes of oral ixazomib maintenance therapy post autologous stem cell transplant (asct) in newly diagnosed multiple myeloma (ndmm) from tourmaline-mm3. abstract pf626. poster presentation. friday, june 14, 5:30 – 7:00 p.m. (poster area). evolving treatment patterns in multiple myeloma (mm) differ by age and region: analysis from insight-mm, a global, prospective, observational study. abstract pf601. poster presentation. friday, june 14, 5:30 – 7:00 p.m. (poster area). long-term proteasome inhibition (ltpi) in patients (pts) with newly diagnosed multiple myeloma (ndmm): us mm-6, a real-world (rw) study transitioning from bortezomib (btz) to ixazomib (ixa). abstract pf729. poster presentation. friday, june 14, 5:30 – 7:00 p.m. (poster area). comparative effectiveness of triplets containing bortezomib (b), carfilzomib (c), daratumumab (d), or ixazomib (i) in relapsed/refractory multiple myeloma (rrmm) in routine care in the us. abstract ps1419. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). characteristics and treatment outcomes of newly diagnosed multiple myeloma (ndmm) non-stem cell transplant (nsct) patients in the uk, germany, and france. abstract ps1411. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). evolving treatment patterns in non-stem cell transplant (nsct) newly diagnosed multiple myeloma (ndmm): results from a real-world chart review in france, germany, and the uk. abstract ps1416. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). impact of patients characteristics on health-related quality of life in patients with relapsed or refractory multiple myeloma: results from the charismma study. abstract pf615. poster presentation. friday, june 14, 5:30 – 7:00 p.m. (poster area). adcetris (brentuximab vedotin) frontline brentuximab vedotin with chemotherapy for stage 3/4 classical hodgkin lymphoma: 3-year update of the echelon-1 study. abstract s820. oral presentation. saturday, june 15, 12:00 – 12:15 p.m. (hall 5). the echelon-2 trial: results of a randomized, double-blind phase 3 study of brentuximab vedotin and chp (a+chp) versus chop in frontline treatment of patients with cd30+ peripheral t-cell lymphomas. abstract ps1070. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). contemporary treatment patterns and response in relapse/refractory cutaneous t-cell lymphoma (ctcl) in clinical practice in france, germany, italy, spain and the united kingdom. abstract ps1256. poster presentation. saturday, june 15, 5:30 – 7:00 p.m. (poster area). for more information, please see asco (https://meetings.asco.org/am/program) and eha (http://www.eha-2019.org/) online programs. about adcetris adcetris is an antibody-drug conjugate (adc) comprising an anti-cd30 monoclonal antibody attached by a protease-cleavable linker to a microtubule disrupting agent, monomethyl auristatin e (mmae), utilizing seattle genetics' proprietary technology. the adc employs a linker system that is designed to be stable in the bloodstream but to release mmae upon internalization into cd30-positive tumor cells. adcetris injection for intravenous infusion has received fda approval for six indications in adult patients with: (1) previously untreated systemic anaplastic large cell lymphoma (salcl) or other cd30-expressing peripheral t-cell lymphomas (ptcl), including angioimmunoblastic t-cell lymphoma and ptcl not otherwise specified, in combination with cyclophosphamide, doxorubicin, and prednisone, (2) previously untreated stage iii or iv classical hodgkin lymphoma (chl), in combination with doxorubicin, vinblastine, and dacarbazine, (3) chl at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-hsct) consolidation, (4) chl after failure of auto-hsct or failure of at least two prior multi-agent chemotherapy regimens in patients who are not auto-hsct candidates, (5) salcl after failure of at least one prior multi-agent chemotherapy regimen, and (6) primary cutaneous anaplastic large cell lymphoma (pcalcl) or cd30-expressing mycosis fungoides (mf) who have received prior systemic therapy. health canada granted adcetris approval with conditions for relapsed or refractory hodgkin lymphoma and salcl in 2013, and non-conditional approval for post-autologous stem cell transplantation (asct) consolidation treatment of hodgkin lymphoma patients at increased risk of relapse or progression in 2017, adults with pcalcl or cd30-expressing mf who have had prior systemic therapy in 2018, and for previously untreated stage iv hodgkin lymphoma in combination with doxorubicin, vinblastine, and dacarbazine in 2019. adcetris received conditional marketing authorization from the european commission in october 2012. the approved indications in europe are: (1) for the treatment of adult patients with relapsed or refractory cd30-positive hodgkin lymphoma following asct, or following at least two prior therapies when asct or multi-agent chemotherapy is not a treatment option, (2) for the treatment of adult patients with relapsed or refractory salcl, (3) for the treatment of adult patients with cd30-positive hodgkin lymphoma at increased risk of relapse or progression following asct, (4) for the treatment of adult patients with cd30-positive cutaneous t-cell lymphoma (ctcl) after at least one prior systemic therapy and (5) for the treatment of adult patients with previously untreated cd30-positive stage iv hodgkin lymphoma in combination with avd. adcetris has received marketing authorization by regulatory authorities in more than 70 countries for relapsed or refractory hodgkin lymphoma and salcl. see important safety information below. adcetris is being evaluated broadly in more than 70 clinical trials, including a phase 3 study in first-line hodgkin lymphoma (echelon-1) and another phase 3 study in first-line cd30-positive peripheral t-cell lymphomas (echelon-2), as well as trials in many additional types of cd30-positive malignancies. seattle genetics and takeda are jointly developing adcetris. under the terms of the collaboration agreement, seattle genetics has u.s. and canadian commercialization rights and takeda has rights to commercialize adcetris in the rest of the world. seattle genetics and takeda are funding joint development costs for adcetris on a 50:50 basis, except in japan where takeda is solely responsible for development costs. adcetris (brentuximab vedotin) important safety information (european union) please refer to summary of product characteristics (smpc) before prescribing. contraindications adcetris is contraindicated for patients with hypersensitivity to brentuximab vedotin and its excipients. in addition, combined use of adcetris with bleomycin causes pulmonary toxicity. special warnings & precautions progressive multifocal leukoencephalopathy (pml): john cunningham virus (jcv) reactivation resulting in progressive multifocal leukoencephalopathy (pml) and death can occur in patients treated with adcetris. pml has been reported in patients who received adcetris after receiving multiple prior chemotherapy regimens. pml is a rare demyelinating disease of the central nervous system that results from reactivation of latent jcv and is often fatal. closely monitor patients for new or worsening neurological, cognitive, or behavioral signs or symptoms, which may be suggestive of pml. suggested evaluation of pml includes neurology consultation, gadolinium-enhanced magnetic resonance imaging of the brain, and cerebrospinal fluid analysis for jcv dna by polymerase chain reaction or a brain biopsy with evidence of jcv. a negative jcv pcr does not exclude pml. additional follow up and evaluation may be warranted if no alternative diagnosis can be established hold dosing for any suspected case of pml and permanently discontinue adcetris if a diagnosis of pml is confirmed. be alert to pml symptoms that the patient may not notice (e.g., cognitive, neurological, or psychiatric symptoms). pancreatitis: acute pancreatitis has been observed in patients treated with adcetris. fatal outcomes have been reported. closely monitor patients for new or worsening abdominal pain, which may be suggestive of acute pancreatitis. patient evaluation may include physical examination, laboratory evaluation for serum amylase and serum lipase, and abdominal imaging, such as ultrasound and other appropriate diagnostic measures. hold adcetris for any suspected case of acute pancreatitis. adcetris should be discontinued if a diagnosis of acute pancreatitis is confirmed. pulmonary toxicity: cases of pulmonary toxicity, some with fatal outcomes, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ards), have been reported in patients receiving adcetris. although a causal association with adcetris has not been established, the risk of pulmonary toxicity cannot be ruled out. promptly evaluate and treat new or worsening pulmonary symptoms (e.g., cough, dyspnoea) appropriately. consider holding dosing during evaluation and until symptomatic improvement. serious infections and opportunistic infections: serious infections such as pneumonia, staphylococcal bacteremia, sepsis/septic shock (including fatal outcomes), and herpes zoster, and opportunistic infections such as pneumocystis jiroveci pneumonia and oral candidiasis have been reported in patients treated with adcetris. carefully monitor patients during treatment for emergence of possible serious and opportunistic infections. infusion-related reactions (irr): immediate and delayed irr, as well as anaphylaxis, have been reported with adcetris. carefully monitor patients during and after an infusion. if anaphylaxis occurs, immediately and permanently discontinue administration of adcetris and administer appropriate medical therapy. if an irr occurs, interrupt the infusion and institute appropriate medical management. the infusion may be restarted at a slower rate after symptom resolution. patients who have experienced a prior irr should be premedicated for subsequent infusions. irrs are more frequent and more severe in patients with antibodies to adcetris. tumor lysis syndrome (tls): tls has been reported with adcetris. patients with rapidly proliferating tumor and high tumor burden are at risk of tls. monitor these patients closely and manage according to best medical practice. peripheral neuropathy (pn): adcetris treatment may cause pn, both sensory and motor. adcetris-induced pn is typically an effect of cumulative exposure to adcetris and is reversible in most cases. monitor patients for symptoms of neuropathy, such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. patients experiencing new or worsening pn may require a delay and a dose reduction or discontinuation of adcetris. hematological toxicities: grade 3 or grade 4 anemia, thrombocytopenia, and prolonged (equal to or greater than one week) grade 3 or grade 4 neutropenia can occur with adcetris. monitor complete blood counts prior to administration of each dose. febrile neutropenia: febrile neutropenia has been reported with adcetris. complete blood counts should be monitored prior to administration of each dose of treatment. closely monitor patients for fever and manage according to best medical practice if febrile neutropenia develops. when adcetris is administered in combination with avd, primary prophylaxis with g-csf is recommended for all patients beginning with the first dose. stevens-johnson syndrome (sjs): sjs and toxic epidermal necrolysis (ten) have been reported with adcetris. fatal outcomes have been reported. discontinue treatment with adcetris if sjs or ten occurs and administer appropriate medical therapy. gastrointestinal (gi) complications: gi complications, some with fatal outcomes, including intestinal obstruction, ileus, enterocolitis, neutropenic colitis, erosion, ulcer, perforation and haemorrhage, have been reported with adcetris. promptly evaluate and treat patients if new or worsening gi symptoms occur. hepatotoxicity: elevations in alanine aminotransferase (alt) and aspartate aminotransferase (ast) have been reported with adcetris. serious cases of hepatotoxicity, including fatal outcomes, have also occurred. pre-existing liver disease, comorbidities, and concomitant medications may also increase the risk. test liver function prior to treatment initiation and routinely monitor during treatment. patients experiencing hepatotoxicity may require a delay, dose modification, or discontinuation of adcetris. hyperglycemia: hyperglycemia has been reported during trials in patients with an elevated body mass index (bmi) with or without a history of diabetes mellitus. closely monitor serum glucose for patients who experiences an event of hyperglycemia. administer anti-diabetic treatment as appropriate. renal and hepatic impairment: there is limited experience in patients with renal and hepatic impairment. available data indicate that mmae clearance might be affected by severe renal impairment, hepatic impairment, and by low serum albumin concentrations. cd30+ ctcl: the size of the treatment effect in cd30 + ctcl subtypes other than mycosis fungoides (mf) and primary cutaneous anaplastic large cell lymphoma (pcalcl) is not clear due to lack of high level evidence. in two single arm phase ii studies of adcetris, disease activity has been shown in the subtypes sÉzary syndrome (ss), lymphomatoid papulosis (lyp) and mixed ctcl histology. these data suggest that efficacy and safety can be extrapolated to other ctcl cd30+ subtypes. carefully consider the benefit-risk per patient and use with caution in other cd30+ ctcl patient types. sodium content in excipients: this medicinal product contains 13.2 mg sodium per vial, equivalent to 0.7% of the who recommended maximum daily intake of 2 g sodium for an adult. interactions patients who are receiving a strong cyp3a4 and p-gp inhibitor, concomitantly with adcetris may have an increased risk of neutropenia. if neutropenia develops, refer to dosing recommendations for neutropenia (see smpc section 4.2). co-administration of adcetris with a cyp3a4 inducer did not alter the plasma exposure of adcetris, but it appeared to reduce plasma concentrations of mmae metabolites that could be assayed. adcetris is not expected to alter the exposure to drugs that are metabolized by cyp3a4 enzymes. pregnancy: advise women of childbearing potential to use two methods of effective contraception during treatment with adcetris and until 6 months after treatment. there are no data from the use of adcetris in pregnant women, although studies in animals have shown reproductive toxicity. do not use adcetris during pregnancy unless the benefit to the mother outweighs the potential risks to the fetus. lactation (breast-feeding): there are no data as to whether adcetris or its metabolites are excreted in human milk, therefore a risk to the newborn/infant cannot be excluded. with the potential risk, a decision should be made whether to discontinue breast-feeding or discontinue/abstain from therapy with adcetris. fertility: in nonclinical studies, adcetris treatment has resulted in testicular toxicity, and may alter male fertility. advise men being treated with adcetris not to father a child during treatment and for up to 6 months following the last dose. effects on ability to drive and use machines: adcetris may have a moderate influence on the ability to drive and use machines. undesirable effects monotherapy: the most frequent adverse reactions (≥10%) were infections, peripheral sensory neuropathy, nausea, fatigue, diarrhoea, pyrexia, upper respiratory tract infection, neutropenia, rash, cough, vomiting, arthralgia, peripheral motor neuropathy, infusion-related reactions, pruritus, constipation, dyspnoea, weight decreased, myalgia and abdominal pain. serious adverse drug reactions occurred in 12% of patients. the frequency of unique serious adverse drug reactions was ≤1%. adverse events led to treatment discontinuation in 24% of patients. combination therapy: in the study of adcetris as combination therapy with avd in 662 patients with previously untreated advanced hl, the most common adverse reactions (≥ 10%) were: neutropenia, nausea, constipation, vomiting, fatigue, peripheral sensory neuropathy, diarrhoea, pyrexia, alopecia, peripheral motor neuropathy, decreased weight, abdominal pain, anaemia, stomatitis, febrile neutropenia, bone pain, insomnia, decreased appetite, cough, headache, arthralgia, back pain, dyspnoea, myalgia, upper respiratory tract infection, alanine aminotransferase increased. serious adverse reactions occurred in 36% of patients. serious adverse reactions occurring in ≥ 3% of patients included febrile neutropenia (17%), pyrexia (6%), and neutropenia (3%). adverse events led to treatment discontinuation in 13% of patients. adcetris (brentuximab vedotin) important safety information (u.s.) boxed warning progressive multifocal leukoencephalopathy (pml): jc virus infection resulting in pml and death can occur in adcetris-treated patients. contraindication adcetris concomitant with bleomycin due to pulmonary toxicity (e.g., interstitial infiltration and/or inflammation). warnings and precautions peripheral neuropathy (pn): adcetris causes pn that is predominantly sensory. cases of motor pn have also been reported. adcetris-induced pn is cumulative. monitor for symptoms such as hypoesthesia, hyperesthesia, paresthesia, discomfort, a burning sensation, neuropathic pain, or weakness. institute dose modifications accordingly. anaphylaxis and infusion reactions: infusion-related reactions (irr), including anaphylaxis, have occurred with adcetris. monitor patients during infusion. if an irr occurs, interrupt the infusion and institute appropriate medical management. if anaphylaxis occurs, immediately and permanently discontinue the infusion and administer appropriate medical therapy. premedicate patients with a prior irr before subsequent infusions. premedication may include acetaminophen, an antihistamine, and a corticosteroid. hematologic toxicities: fatal and serious cases of febrile neutropenia have been reported with adcetris. prolonged (≥1 week) severe neutropenia and grade 3 or 4 thrombocytopenia or anemia can occur with adcetris.administer g-csf primary prophylaxis beginning with cycle 1 for patients who receive adcetris in combination with chemotherapy for previously untreated stage iii/iv chl or previously untreated ptcl.monitor complete blood counts prior to each adcetris dose. monitor more frequently for patients with grade 3 or 4 neutropenia. monitor patients for fever. if grade 3 or 4 neutropenia develops, consider dose delays, reductions, discontinuation, or g-csf prophylaxis with subsequent doses. serious infections and opportunistic infections: infections such as pneumonia, bacteremia, and sepsis or septic shock (including fatal outcomes) have been reported in adcetris-treated patients. closely monitor patients during treatment for bacterial, fungal, or viral infections. tumor lysis syndrome: closely monitor patients with rapidly proliferating tumor and high tumor burden. increased toxicity in the presence of severe renal impairment: the frequency of ≥grade 3 adverse reactions and deaths was greater in patients with severe renal impairment compared to patients with normal renal function. avoid use in patients with severe renal impairment. increased toxicity in the presence of moderate or severe hepatic impairment: the frequency of ≥grade 3 adverse reactions and deaths was greater in patients with moderate or severe hepatic impairment compared to patients with normal hepatic function. avoid use in patients with moderate or severe hepatic impairment. hepatotoxicity: fatal and serious cases have occurred in adcetris-treated patients. cases were consistent with hepatocellular injury, including elevations of transaminases and/or bilirubin, and occurred after the first adcetris dose or rechallenge. preexisting liver disease, elevated baseline liver enzymes, and concomitant medications may increase the risk. monitor liver enzymes and bilirubin. patients with new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of adcetris. pml: fatal cases of jc virus infection resulting in pml have been reported in adcetris-treated patients. first onset of symptoms occurred at various times from initiation of adcetris, with some cases occurring within 3 months of initial exposure. in addition to adcetris therapy, other possible contributory factors include prior therapies and underlying disease that may cause immunosuppression. consider pml diagnosis in patients with new-onset signs and symptoms of central nervous system abnormalities. hold adcetris if pml is suspected and discontinue adcetris if pml is confirmed. pulmonary toxicity: fatal and serious events of noninfectious pulmonary toxicity, including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome, have been reported. monitor patients for signs and symptoms, including cough and dyspnea. in the event of new or worsening pulmonary symptoms, hold adcetris dosing during evaluation and until symptomatic improvement. serious dermatologic reactions: fatal and serious cases of stevens-johnson syndrome (sjs) and toxic epidermal necrolysis (ten) have been reported with adcetris. if sjs or ten occurs, discontinue adcetris and administer appropriate medical therapy. gastrointestinal (gi) complications: fatal and serious cases of acute pancreatitis have been reported. other fatal and serious gi complications include perforation, hemorrhage, erosion, ulcer, intestinal obstruction, enterocolitis, neutropenic colitis, and ileus. lymphoma with preexisting gi involvement may increase the risk of perforation. in the event of new or worsening gi symptoms, including severe abdominal pain, perform a prompt diagnostic evaluation and treat appropriately. embryo-fetal toxicity: based on the mechanism of action and animal studies, adcetris can cause fetal harm. advise females of reproductive potential of the potential risk to the fetus, and to avoid pregnancy during adcetris treatment and for at least 6 months after the final dose of adcetris. most common (≥20% in any study) adverse reactions peripheral neuropathy, fatigue, nausea, diarrhea, neutropenia, upper respiratory tract infection, pyrexia, constipation, vomiting, alopecia, decreased weight, abdominal pain, anemia, stomatitis, lymphopenia, and mucositis. drug interactions concomitant use of strong cyp3a4 inhibitors or inducers has the potential to affect the exposure to monomethyl auristatin e (mmae). use in specific populations moderate or severe hepatic impairment or severe renal impairment: mmae exposure and adverse reactions are increased. avoid use. advise males with female sexual partners of reproductive potential to use effective contraception during adcetris treatment and for at least 6 months after the final dose of adcetris. advise patients to report pregnancy immediately and avoid breastfeeding while receiving adcetris. for additional important safety information, including boxed warning, please see the full prescribing information for adcetris at www.seattlegenetics.com or http://www.adcetris.com. about alunbrig® (brigatinib) alunbrig is a targeted cancer medicine discovered by ariad pharmaceuticals, inc., which was acquired by takeda in february 2017. in april 2017, alunbrig received accelerated approval from the u.s. food and drug administration (fda) for alk+ metastatic nsclc patients who have progressed on or are intolerant to crizotinib. this indication is approved under accelerated approval based on tumor response rate and duration of response. continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. in july 2018, health canada approved alunbrig for the treatment of adult patients with alk+ metastatic nsclc who have progressed on or who were intolerant to an alk inhibitor (crizotinib). the fda and health canada approvals of alunbrig were primarily based on results from the pivotal phase 2 alta (alk in lung cancer trial of ap26113) trial. in november 2018, the european commission (ec) granted marketing authorization for alunbrig as a monotherapy for the treatment of adult patients with alk+ advanced nsclc previously treated with crizotinib. alunbrig received breakthrough therapy designation from the fda for the treatment of patients with alk+ nsclc whose tumors are resistant to crizotinib and was granted orphan drug designation by the fda for the treatment of alk+ nsclc, ros1+ and egfr+ nsclc. the brigatinib clinical development program further reinforces takeda’s ongoing commitment to developing innovative therapies for people living with alk+ nsclc worldwide and the healthcare professionals who treat them. the comprehensive program includes the following clinical trials: phase 1/2 trial, which was designed to evaluate the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of alunbrig pivotal phase 2 alta trial investigating the efficacy and safety of alunbrig at two dosing regimens in patients with alk+ locally advanced or metastatic nsclc who had progressed on crizotinib phase 3 alta-1l, a global randomized trial assessing the efficacy and safety of alunbrig in comparison to crizotinib in patients with alk+ locally advanced or metastatic nsclc who have not received prior treatment with an alk inhibitor phase 2 single-arm, multicenter trial in japanese patients with alk+ nsclc, focusing on patients who have progressed on alectinib phase 2 global, single-arm trial evaluating alunbrig in patients with advanced alk+ nsclc who have progressed on alectinib or ceritinib phase 3 global randomized trial comparing the efficacy and safety of alunbrig versus alectinib in participants with alk+ nsclc who have progressed on crizotinib for additional information on the brigatinib clinical trials, please visit www.clinicaltrials.gov. important safety information warnings and precautions interstitial lung disease (ild)/pneumonitis: severe, life-threatening, and fatal pulmonary adverse reactions consistent with interstitial lung disease (ild)/pneumonitis have occurred with alunbrig. in trial alta (alta), ild/pneumonitis occurred in 3.7% of patients in the 90 mg group (90 mg once daily) and 9.1% of patients in the 90→180 mg group (180 mg once daily with 7-day lead-in at 90 mg once daily). adverse reactions consistent with possible ild/pneumonitis occurred early (within 9 days of initiation of alunbrig; median onset was 2 days) in 6.4% of patients, with grade 3 to 4 reactions occurring in 2.7%. monitor for new or worsening respiratory symptoms (e.g., dyspnea, cough, etc.), particularly during the first week of initiating alunbrig. withhold alunbrig in any patient with new or worsening respiratory symptoms, and promptly evaluate for ild/pneumonitis or other causes of respiratory symptoms (e.g., pulmonary embolism, tumor progression, and infectious pneumonia). for grade 1 or 2 ild/pneumonitis, either resume alunbrig with dose reduction after recovery to baseline or permanently discontinue alunbrig. permanently discontinue alunbrig for grade 3 or 4 ild/pneumonitis or recurrence of grade 1 or 2 ild/pneumonitis. hypertension: in alta, hypertension was reported in 11% of patients in the 90 mg group who received alunbrig and 21% of patients in the 90→180 mg group. grade 3 hypertension occurred in 5.9% of patients overall. control blood pressure prior to treatment with alunbrig. monitor blood pressure after 2 weeks and at least monthly thereafter during treatment with alunbrig. withhold alunbrig for grade 3 hypertension despite optimal antihypertensive therapy. upon resolution or improvement to grade 1 severity, resume alunbrig at a reduced dose. consider permanent discontinuation of treatment with alunbrig for grade 4 hypertension or recurrence of grade 3 hypertension. use caution when administering alunbrig in combination with antihypertensive agents that cause bradycardia. bradycardia: bradycardia can occur with alunbrig. in alta, heart rates less than 50 beats per minute (bpm) occurred in 5.7% of patients in the 90 mg group and 7.6% of patients in the 90→180 mg group. grade 2 bradycardia occurred in 1 (0.9%) patient in the 90 mg group. monitor heart rate and blood pressure during treatment with alunbrig. monitor patients more frequently if concomitant use of drug known to cause bradycardia cannot be avoided. for symptomatic bradycardia, withhold alunbrig and review concomitant medications for those known to cause bradycardia. if a concomitant medication known to cause bradycardia is identified and discontinued or dose adjusted, resume alunbrig at the same dose following resolution of symptomatic bradycardia; otherwise, reduce the dose of alunbrig following resolution of symptomatic bradycardia. discontinue alunbrig for life-threatening bradycardia if no contributing concomitant medication is identified. visual disturbance: in alta, adverse reactions leading to visual disturbance including blurred vision, diplopia, and reduced visual acuity, were reported in 7.3% of patients treated with alunbrig in the 90 mg group and 10% of patients in the 90→180 mg group. grade 3 macular edema and cataract occurred in one patient each in the 90→180 mg group. advise patients to report any visual symptoms. withhold alunbrig and obtain an ophthalmologic evaluation in patients with new or worsening visual symptoms of grade 2 or greater severity. upon recovery of grade 2 or grade 3 visual disturbances to grade 1 severity or baseline, resume alunbrig at a reduced dose. permanently discontinue treatment with alunbrig for grade 4 visual disturbances. creatine phosphokinase (cpk) elevation: in alta, creatine phosphokinase (cpk) elevation occurred in 27% of patients receiving alunbrig in the 90 mg group and 48% of patients in the 90 mg→180 mg group. the incidence of grade 3-4 cpk elevation was 2.8% in the 90 mg group and 12% in the 90→180 mg group. dose reduction for cpk elevation occurred in 1.8% of patients in the 90 mg group and 4.5% in the 90→180 mg group. advise patients to report any unexplained muscle pain, tenderness, or weakness. monitor cpk levels during alunbrig treatment. withhold alunbrig for grade 3 or 4 cpk elevation. upon resolution or recovery to grade 1 or baseline, resume alunbrig at the same dose or at a reduced dose. pancreatic enzyme elevation: in alta, amylase elevation occurred in 27% of patients in the 90 mg group and 39% of patients in the 90→180 mg group. lipase elevations occurred in 21% of patients in the 90 mg group and 45% of patients in the 90→180 mg group. grade 3 or 4 amylase elevation occurred in 3.7% of patients in the 90 mg group and 2.7% of patients in the 90→180 mg group. grade 3 or 4 lipase elevation occurred in 4.6% of patients in the 90 mg group and 5.5% of patients in the 90→180 mg group. monitor lipase and amylase during treatment with alunbrig. withhold alunbrig for grade 3 or 4 pancreatic enzyme elevation. upon resolution or recovery to grade 1 or baseline, resume alunbrig at the same dose or at a reduced dose. hyperglycemia: in alta, 43% of patients who received alunbrig experienced new or worsening hyperglycemia. grade 3 hyperglycemia, based on laboratory assessment of serum fasting glucose levels, occurred in 3.7% of patients. two of 20 (10%) patients with diabetes or glucose intolerance at baseline required initiation of insulin while receiving alunbrig. assess fasting serum glucose prior to initiation of alunbrig and monitor periodically thereafter. initiate or optimize anti-hyperglycemic medications as needed. if adequate hyperglycemic control cannot be achieved with optimal medical management, withhold alunbrig until adequate hyperglycemic control is achieved and consider reducing the dose of alunbrig or permanently discontinuing alunbrig. embryo-fetal toxicity: based on its mechanism of action and findings in animals, alunbrig can cause fetal harm when administered to pregnant women. there are no clinical data on the use of alunbrig in pregnant women. advise pregnant women of the potential risk to a fetus. advise females of reproductive potential to use effective non-hormonal contraception during treatment with alunbrig and for at least 4 months following the final dose. advise males with female partners of reproductive potential to use effective contraception during treatment and for at least 3 months after the last dose of alunbrig. adverse reactions serious adverse reactions occurred in 38% of patients in the 90 mg group and 40% of patients in the 90→180 mg group. the most common serious adverse reactions were pneumonia (5.5% overall, 3.7% in the 90 mg group, and 7.3% in the 90→180 mg group) and ild/pneumonitis (4.6% overall, 1.8% in the 90 mg group and 7.3% in the 90→180 mg group). fatal adverse reactions occurred in 3.7% of patients and consisted of pneumonia (2 patients), sudden death, dyspnea, respiratory failure, pulmonary embolism, bacterial meningitis and urosepsis (1 patient each). the most common adverse reactions (≥25%) in the 90 mg group were nausea (33%), fatigue (29%), headache (28%), and dyspnea (27%) and in the 90→180 mg group were nausea (40%), diarrhea (38%), fatigue (36%), cough (34%), and headache (27%). drug interactions cyp3a inhibitors: avoid coadministration of alunbrig with strong or moderate cyp3a inhibitors. avoid grapefruit or grapefruit juice as it may also increase plasma concentrations of brigatinib. if coadministration of a strong or moderate cyp3a inhibitor cannot be avoided, reduce the dose of alunbrig. cyp3a inducers: avoid coadministration of alunbrig with strong or moderate cyp3a inducers. if coadministration of moderate cyp3a inducers cannot be avoided, increase the dose of alunbrig cyp3a substrates: coadministration of alunbrig with sensitive cyp3a substrates, including hormonal contraceptives, can result in decreased concentrations and loss of efficacy of sensitive cyp3a substrates. use in specific populations pregnancy: alunbrig can cause fetal harm. advise females of reproductive potential of the potential risk to a fetus. lactation: there are no data regarding the secretion of brigatinib in human milk or its effects on the breastfed infant or milk production. because of the potential adverse reactions in breastfed infants, advise lactating women not to breastfeed during treatment with alunbrig. females and males of reproductive potential: pregnancy testing: verify pregnancy status in females of reproductive potential prior to initiating alunbrig contraception: advise females of reproductive potential to use effective non-hormonal contraception during treatment with alunbrig and for at least 4 months after the final dose. advise males with female partners of reproductive potential to use effective contraception during treatment with alunbrig and for at least 3 months after the final dose. infertility: alunbrig may cause reduced fertility in males. pediatric use: the safety and effectiveness of alunbrig in pediatric patients have not been established. geriatric use: clinical studies of alunbrig did not include sufficient numbers of patients aged 65 years and older to determine whether they respond differently from younger patients. hepatic or renal impairment: no dose adjustment is recommended for patients with mild or moderate hepatic impairment or mild or moderate renal impairment. reduce the dose of alunbrig for patients with severe hepatic impairment or severe renal impairment. please see the full u.s. prescribing information for alunbrig at www.alunbrig.com about iclusig® (ponatinib) tablets iclusig is a kinase inhibitor primarily targeting bcr-abl1, an abnormal tyrosine kinase that is expressed in chronic myeloid leukemia (cml) and philadelphia chromosome-positive acute lymphoblastic leukemia (ph+ all). iclusig is a targeted cancer medicine developed using a computational and structure-based drug-design platform, specifically designed to inhibit the activity of bcr-abl1 and its mutations. iclusig targets native bcr-abl1, as well as bcr-abl1 treatment-resistant mutations, including the most resistant t315i mutation. iclusig is the only approved tki that demonstrates activity against the t315i gatekeeper mutation of bcr-abl1. this mutation has been associated with resistance to all other approved tkis. iclusig which received full approval from the fda in november 2016, is also approved in the eu, australia, switzerland, israel, canada and japan. in the u.s., iclusig is indicated for: treatment of adult patients with chronic-phase, accelerated-phase or blast-phase cml (cp-cml, ap-cml or bp-cml) or ph+ all for whom no other tyrosine kinase inhibitor (tki) therapy is indicated. treatment for adult patients with t315i-positive cml (cp, ap or bp) or t315i-positive ph+ all. limitations of use: iclusig is not indicated and is not recommended for the treatment of patients with newly diagnosed cp-cml. iclusig (ponatinib) important safety information (u.s.) warning: arterial occlusion, venous thromboembolism, heart failure, and hepatotoxicity see full prescribing information for complete boxed warning. arterial occlusion has occurred in at least 35% of iclusig® (ponatinib)-treated patients including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease, and the need for urgent revascularization procedures. patients with and without cardiovascular risk factors, including patients less than 50 years old, experienced these events. interrupt or stop iclusig immediately for arterial occlusion. a benefit-risk consideration should guide a decision to restart iclusig. venous thromboembolism has occurred in 6% of iclusig-treated patients. monitor for evidence of thromboembolism. consider dose modification or discontinuation of iclusig in patients who develop serious venous thromboembolism. heart failure, including fatalities occurred in 9% of iclusig treated patients. monitor cardiac function. interrupt or stop iclusig for new or worsening heart failure. hepatotoxicity, liver failure and death have occurred in iclusig-treated patients. monitor hepatic function. interrupt iclusig if hepatotoxicity is suspected. warnings and precautions arterial occlusions: arterial occlusions, including fatal myocardial infarction, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease have occurred in at least 35% of iclusig-treated patients from the phase 1 and phase 2 trials. in the phase 2 trial, 33% (150/449) of iclusig-treated patients experienced a cardiac vascular (21%), peripheral vascular (12%), or cerebrovascular (9%) arterial occlusive event; some patients experienced more than 1 type of event. fatal and life-threatening events have occurred within 2 weeks of starting treatment, with doses as low as 15 mg per day. iclusig can also cause recurrent or multi-site vascular occlusion. patients have required revascularization procedures. the median time to onset of the first cardiac vascular, cerebrovascular, and peripheral vascular arterial occlusive events was 193, 526, and 478 days, respectively. patients with and without cardiovascular risk factors, some age 50 years or younger, experienced these events. the most common risk factors observed with these events were hypertension, hyperlipidemia, and history of cardiac disease. arterial occlusive events were more frequent with increasing age and in patients with a history of ischemia, hypertension, diabetes, or hyperlipidemia. in patients suspected of developing arterial occlusive events, interrupt or stop iclusig. venous thromboembolism: venous thromboembolic events occurred in 6% (25/449) of iclusig-treated patients with an incidence rate of 5% (13/270 cp-cml), 4% (3/85 ap-cml), 10% (6/62 bp-cml) and 9% (3/32 ph+ all). events included: deep venous thrombosis, pulmonary embolism, superficial thrombophlebitis, and retinal vein thrombosis with vision loss. consider dose modification or discontinuation of iclusig in patients who develop serious venous thromboembolism. heart failure: fatal or serious heart failure or left ventricular dysfunction occurred in 6% of iclusig-treated patients (29/449). nine percent of patients (39/449) experienced any grade of heart failure or left ventricular dysfunction. the most frequently reported heart failure events were congestive cardiac failure and decreased ejection fraction (14 patients each; 3%). monitor patients for signs or symptoms consistent with heart failure and treat as clinically indicated, including interruption of iclusig. consider discontinuation if serious heart failure develops. hepatotoxicity: iclusig can cause hepatotoxicity, including liver failure and death. fulminant hepatic failure leading to death occurred in a patient within one week of starting iclusig. two additional fatal cases of acute liver failure also occurred. the fatal cases occurred in patients with bp-cml or ph+ all. severe hepatotoxicity occurred in all disease cohorts, with 11% (50/449) experiencing grade 3 or 4 hepatotoxicity. the most common forms of hepatotoxicity were elevations of ast or alt (54% all grades, 8% grade 3 or 4, 5% not reversed at last follow-up), bilirubin, and alkaline phosphatase. hepatotoxic events were observed in 29% of patients. the median time to onset of hepatotoxicity event was 3 months. monitor liver function tests at baseline, then at least monthly or as clinically indicated. interrupt, reduce or discontinue iclusig as clinically indicated. hypertension: treatment-emergent elevation of systolic or diastolic blood pressure (bp) occurred in 68% (306/449) of iclusig-treated patients. fifty-three patients (12%) experienced treatment-emergent symptomatic hypertension as a serious adverse reaction, including hypertensive crisis. patients may require urgent clinical intervention for hypertension associated with confusion, headache, chest pain, or shortness of breath. in patients with baseline systolic bp2% of the patients (treatment-emergent), serious cases included: pleural effusion (7/449, 2%), pericardial effusion (4/449, 1%), and edema peripheral (2/449, <1%). in total, fluid retention occurred in 31% of the patients. the most common fluid retention events were peripheral edema (17%), pleural effusion (8%), pericardial effusion (4%) and peripheral swelling (3%). monitor patients for fluid retention and manage patients as clinically indicated. interrupt, reduce, or discontinue iclusig as clinically indicated. cardiac arrhythmias: arrhythmias occurred in 19% (86/449) of iclusig-treated patients, of which 7% (33/449) were grade 3 or greater. arrhythmia of ventricular origin was reported in 3% (3/86) of all arrhythmias, with one case being grade 3 or greater. symptomatic bradyarrhythmias that led to pacemaker implantation occurred in 1% (3/449) of iclusig-treated patients. atrial fibrillation was the most common arrhythmia and occurred in 7% (31/449) of patients, approximately half of which were grade 3 or 4. other grade 3 or 4 arrhythmia events included syncope (9 patients; 2.0%), tachycardia and bradycardia (2 patients each 0.4%), and electrocardiogram qt prolonged, atrial flutter, supraventricular tachycardia, ventricular tachycardia, atrial tachycardia, atrioventricular block complete, cardio-respiratory arrest, loss of consciousness, and sinus node dysfunction (1 patient each 0.2%). for 27 patients, the event led to hospitalization. in patients with signs and symptoms suggestive of slow heart rate (fainting, dizziness) or rapid heart rate (chest pain, palpitations or dizziness), interrupt iclusig and evaluate. myelosuppression: myelosuppression was reported as an adverse reaction in 59% (266/449) of iclusig-treated patients and grade 3/4 myelosuppression occurred in 50% (226/449) of patients. the incidence of these events was greater in patients with ap-cml, bp-cml, and ph+ all than in patients with cp-cml. severe myelosuppression (grade 3 or 4) was observed early in treatment, with a median onset time of 1 month (range <1-40 months). obtain complete blood counts every 2 weeks for the first 3 months and then monthly or as clinically indicated, and adjust the dose as recommended. tumor lysis syndrome: two patients (<1%, one with ap-cml and one with bp-cml) treated with iclusig developed serious tumor lysis syndrome. hyperuricemia occurred in 7% (31/449) of patients. due to the potential for tumor lysis syndrome in patients with advanced disease, ensure adequate hydration and treat high uric acid levels prior to initiating therapy with iclusig. reversible posterior leukoencephalopathy syndrome (rpls): postmarketing cases of reversible posterior leukoencephalopathy syndrome (rpls—also known as posterior reversible encephalopathy syndrome (pres)) have been reported in iclusig-treated patients. rpls is a neurological disorder that can present with signs and symptoms such as seizure, headache, decreased alertness, altered mental functioning, vision loss, and other visual and neurological disturbances. hypertension is often present and diagnosis is made with supportive findings on magnetic resonance imaging (mri) of the brain. if rpls is diagnosed, interrupt iclusig treatment and resume treatment only once the event is resolved and if the benefit of continued treatment outweighs the risk of rpls. compromised wound healing and gastrointestinal perforation: since iclusig may compromise wound healing, interrupt iclusig for at least 1 week prior to major surgery. serious gastrointestinal perforation (fistula) occurred in one patient 38 days post-cholecystectomy. embryo-fetal toxicity: based on its mechanism of action and findings from animal studies, iclusig can cause fetal harm when administered to a pregnant woman. in animal reproduction studies, oral administration of ponatinib to pregnant rats during organogenesis caused adverse developmental effects at exposures lower than human exposures at the recommended human dose. advise pregnant women of the potential risk to the fetus. advise females of reproductive potential to use effective contraception during treatment with iclusig and for 3 weeks after the last dose. adverse reactions most common adverse reactions: overall, the most common non-hematologic adverse reactions (≥20%) were abdominal pain, rash, constipation, headache, dry skin, arterial occlusion, fatigue, hypertension, pyrexia, arthralgia, nausea, diarrhea, lipase increased, vomiting, myalgia and pain in extremity. hematologic adverse reactions included thrombocytopenia, anemia, neutropenia, lymphopenia, and leukopenia. to report suspected adverse reactions, contact takeda at 1-844-t-1point (1-844-817-6468) or fda at 1-800-fda-1088 or www.fda.gov/medwatch. drug interactions strong cyp3a inhibitors: avoid concurrent use or reduce iclusig dose if co-administration cannot be avoided. strong cyp3a inducers: avoid concurrent use. use in specific populations females and males of reproductive potential: iclusig can cause fetal harm when administered to pregnant women. advise females to use effective contraception during treatment with iclusig and for 3 weeks after the last dose. ponatinib may impair fertility in females and it is not known if these effects are reversible. verify pregnancy status of females of reproductive potential prior to initiating iclusig. lactation: advise women not to breastfeed during treatment with iclusig and for six days after last dose. for us prescribing information: http://www.iclusig.com/pi about ninlaro™ (ixazomib) capsules ninlaro™ (ixazomib) is an oral proteasome inhibitor which is being studied across the continuum of multiple myeloma treatment settings as well as systemic light-chain (al) amyloidosis. ninlaro was approved by the u.s. food and drug administration (fda) in november 2015 following a priority review and by the european commission in november 2016. in the u.s. and europe, ninlaro is indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. ninlaro is currently approved in more than 60 countries, including the united states, japan and in the european union, with more than 10 regulatory filings currently under review. it was the first oral proteasome inhibitor to enter phase 3 clinical trials and to receive approval. ixazomib was granted orphan drug designation in multiple myeloma in both the u.s. and europe in 2011 and for al amyloidosis in both the u.s. and europe in 2012. ixazomib received breakthrough therapy status by the u.s. fda for relapsed or refractory al amyloidosis, a related ultra orphan disease, in 2014. the japanese ministry of health, labour and welfare granted orphan drug designation to ixazomib in 2016 and granted sakigake designation to ixazomib for al amyloidosis in 2019. the comprehensive ixazomib clinical development program, tourmaline, includes a total of five ongoing pivotal trials, which together are investigating major multiple myeloma patient populations, and one in al amyloidosis: tourmaline-mm1, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in relapsed and/or refractory multiple myeloma tourmaline-mm2, investigating ixazomib vs. placebo in combination with lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma tourmaline-mm3, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma following induction therapy and autologous stem cell transplant (asct) tourmaline-mm4, investigating ixazomib vs. placebo as maintenance therapy in patients with newly diagnosed multiple myeloma who have not undergone asct; this study is currently enrolling tourmaline-al1, investigating ixazomib plus dexamethasone vs. physician choice of selected regimens in patients with relapsed or refractory al amyloidosis; this study is currently enrolling for more information about actively enrolling tourmaline studies please visit: https://www.tourmalinetrials.com/ in addition to the tourmaline program, ixazomib is being evaluated in multiple therapeutic combinations for various patient populations in investigator initiated studies globally. ninlaro™ (ixazomib) capsules: global important safety information special warnings and precautions thrombocytopenia has been reported with ninlaro (28% vs. 14% in the ninlaro and placebo regimens, respectively) with platelet nadirs typically occurring between days 14-21 of each 28-day cycle and recovery to baseline by the start of the next cycle. it did not result in an increase in hemorrhagic events or platelet transfusions. monitor platelet counts at least monthly during treatment with ninlaro and consider more frequent monitoring during the first three cycles. manage with dose modifications and platelet transfusions as per standard medical guidelines. gastrointestinal toxicities have been reported in the ninlaro and placebo regimens respectively, such as diarrhea (42% vs. 36%), constipation (34% vs. 25%), nausea (26% vs. 21%), and vomiting (22% vs. 11%), occasionally requiring use of antiemetic and anti-diarrheal medications, and supportive care. peripheral neuropathy was reported with ninlaro (28% vs. 21% in the ninlaro and placebo regimens, respectively). the most commonly reported reaction was peripheral sensory neuropathy (19% and 14% in the ninlaro and placebo regimens, respectively). peripheral motor neuropathy was not commonly reported in either regimen (< 1%). monitor patients for symptoms of peripheral neuropathy and adjust dosing as needed. peripheral edema was reported with ninlaro (25% vs. 18% in the ninlaro and placebo regimens, respectively). evaluate patients for underlying causes and provide supportive care, as necessary. adjust the dose of dexamethasone per its prescribing information or the dose of ninlaro for severe symptoms. cutaneous reactions occurred in 19% of patients in the ninlaro regimen compared to 11% of patients in the placebo regimen. the most common type of rash reported in both regimens was maculo-papular and macular rash. manage rash with supportive care, dose modification or discontinuation. hepatotoxicity, drug-induced liver injury, hepatocellular injury, hepatic steatosis, and hepatitis cholestatic have been uncommonly reported with ninlaro. monitor hepatic enzymes regularly and adjust dose for grade 3 or 4 symptoms. pregnancy- ninlaro can cause fetal harm. advise male and females patients of reproductive potential to use contraceptive measures during treatment and for an additional 90 days after the final dose of ninlaro. women of childbearing potential should avoid becoming pregnant while taking ninlaro due to potential hazard to the fetus. women using hormonal contraceptives should use an additional barrier method of contraception. lactation- it is not known whether ninlaro or its metabolites are excreted in human milk. there could be potential adverse events in nursing infants and therefore breastfeeding should be discontinued. special patient populations hepatic impairment: reduce the ninlaro starting dose to 3 mg in patients with moderate or severe hepatic impairment. renal impairment: reduce the ninlaro starting dose to 3 mg in patients with severe renal impairment or end-stage renal disease (esrd) requiring dialysis. ninlaro is not dialyzable and, therefore, can be administered without regard to the timing of dialysis. drug interactions co-administration of strong cyp3a inducers with ninlaro is not recommended. adverse reactions the most frequently reported adverse reactions (≥ 20%) in the ninlaro regimen, and greater than in the placebo regimen, were diarrhea (42% vs. 36%), constipation (34% vs. 25%), thrombocytopenia (28% vs. 14%), peripheral neuropathy (28% vs. 21%), nausea (26% vs. 21%), peripheral edema (25% vs. 18%), vomiting (22% vs. 11%), and back pain (21% vs. 16%). serious adverse reactions reported in ≥ 2% of patients included thrombocytopenia (2%) and diarrhea (2%). for each adverse reaction, one or more of the three drugs was discontinued in ≤ 1% of patients in the ninlaro regimen. for european union summary of product characteristics: http://www.ema.europa.eu/docs/en_gb/document_library/epar_-_product_information/human/003844/wc500217620.pdf for us prescribing information: https://www.ninlarohcp.com/pdf/prescribing-information.pdf for canada product monograph: http://www.takedacanada.com/ninlaropm about takeda pharmaceutical company limited takeda pharmaceutical company limited (tse:4502/nyse:tak) is a global, values-based, r&d-driven biopharmaceutical leader headquartered in japan, committed to bringing better health and a brighter future to patients by translating science into highly-innovative medicines. takeda focuses its r&d efforts on four therapeutic areas: oncology, gastroenterology (gi), neuroscience and rare diseases. we also make targeted r&d investments in plasma-derived therapies and vaccines. we are focusing on developing highly innovative medicines that contribute to making a difference in people's lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative r&d engine and capabilities to create a robust, modality-diverse pipeline. our employees are committed to improving quality of life for patients and to working with our partners in health care in approximately 80 countries and regions. for more information, visit https://www.takeda.com
